Bristol Myers Squibb (BMY) Rises But Trails Market: What Investors Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.26, marking a +0.59% move from the previous day.
Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now
Bristol Meyers Squibb's stock is down nearly 15% over the past 3 years and currently trades at a price to earnings of less than 15x, indicating it is undervalued. BMY recently announced a deal wort...
Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study
Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.
7 Stocks with Strong Insider Buying: December 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is und...
Is Bristol Myers Squibb Stock a Buy Now?
Bristol Myers Squibb is dealing with a dreaded risk drugmakers face: patent cliffs. However, the company's new medicines are slowly but surely rising in importance.
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024.
Bristol Myers Squibb (BMY) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.47, marking a -0.75% move from the previous day.
Trade Tracker: Jim Lebenthal sells Nike and Bristol-Myers, buys UnitedHealth
Jim Lebenthal, Cerity Partners chief equity strategist, joins CNBC's "Halftime Report" to discuss his latest trades.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock
Bristol-Myers Squibb announces an up-to-$8.4 billion license deal with SystImmune to bolster its oncology pipeline. The initial payment of $800 million is relatively low for BMY, with potential mil...
Bristol Myers, SystImmune to collaborate for cancer drug development
Bristol Myers Squibb said on Monday it will make an upfront payment of $800 million to SystImmune to co-develop and co-commercialize a type of antibody-drug conjugates (ADC) treatment that precisel...
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Chimeric antigen receptor T-cell medicines could have more risks than previously known. Novartis' drug Kymriah is going to be under the most scrutiny for now.
Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?
Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.
Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion
Bristol Myers Squibb Co. BMY, -0.70% announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to about $5 billion. The stock rose 1% premarket but is do...
Bristol Myers Squibb raises dividend by 5.3%
Bristol Myers Squibb Co. BMY, -0.70% said late Wednesday that its board has declared a quarterly dividend of 60 cents a share, a 5.3% increase over last year's dividend of 57 cents a share. The div...
Related Companies